» Articles » PMID: 31604989

Vitamin K1 Prevents Diabetic Cataract by Inhibiting Lens Aldose Reductase 2 (ALR2) Activity

Overview
Journal Sci Rep
Specialty Science
Date 2019 Oct 13
PMID 31604989
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

This study investigated the potential of vitamin K1 as a novel lens aldose reductase inhibitor in a streptozotocin-induced diabetic cataract model. A single, intraperitoneal injection of streptozotocin (STZ) (35 mg/kg) resulted in hyperglycemia, activation of lens aldose reductase 2 (ALR2) and accumulation of sorbitol in eye lens which could have contributed to diabetic cataract formation. However, when diabetic rats were treated with vitamin K1 (5 mg/kg, sc, twice a week) it resulted in lowering of blood glucose and inhibition of lens aldose reductase activity because of which there was a corresponding decrease in lens sorbitol accumulation. These results suggest that vitamin K1 is a potent inhibitor of lens aldose reductase enzyme and we made an attempt to understand the nature of this inhibition using crude lens homogenate as well as recombinant human aldose reductase enzyme. Our results from protein docking and spectrofluorimetric analyses clearly show that vitamin K1 is a potent inhibitor of ALR2 and this inhibition is primarily mediated by the blockage of DL-glyceraldehyde binding to ALR2. At the same time docking also suggests that vitamin K1 overlaps at the NADPH binding site of ALR2, which probably shows that vitamin K1 could possibly bind both these sites in the enzyme. Another deduction that we can derive from the experiments performed with pure protein is that ALR2 has three levels of affinity, first for NADPH, second for vitamin K1 and third for the substrate DL-glyceraldehyde. This was evident based on the dose-dependency experiments performed with both NADPH and DL-glyceraldehyde. Overall, our study shows the potential of vitamin K1 as an ALR2 inhibitor which primarily blocks enzyme activity by inhibiting substrate interaction of the enzyme. Further structural studies are needed to fully comprehend the exact nature of binding and inhibition of ALR2 by vitamin K1 that could open up possibilities of its therapeutic application.

Citing Articles

Effects of Angiotensin Receptor Blockers on Streptozotocin-Induced Diabetic Cataracts.

Ishigooka G, Mizuno H, Oosuka S, Jin D, Takai S, Kida T J Clin Med. 2023; 12(20).

PMID: 37892765 PMC: 10607684. DOI: 10.3390/jcm12206627.


Vitamin K and the Visual System-A Narrative Review.

Mong M Nutrients. 2023; 15(8).

PMID: 37111170 PMC: 10143727. DOI: 10.3390/nu15081948.


Pre-hyperglycemia immune cell trafficking underlies subclinical diabetic cataractogenesis.

Ranaei Pirmardan E, Zhang Y, Barakat A, Naseri M, Russmann C, Hafezi-Moghadam A J Biomed Sci. 2023; 30(1):6.

PMID: 36694206 PMC: 9872438. DOI: 10.1186/s12929-023-00895-6.


Ghrelin Mitigates High-Glucose-Induced Oxidative Damage and Apoptosis in Lens Epithelial Cells.

Bai J, Jiang G, Zhao M, Wang S J Diabetes Res. 2023; 2022:1373533.

PMID: 36589628 PMC: 9797303. DOI: 10.1155/2022/1373533.


Physiological and Pathological Roles of Aldose Reductase.

Singh M, Kapoor A, Bhatnagar A Metabolites. 2021; 11(10).

PMID: 34677370 PMC: 8541668. DOI: 10.3390/metabo11100655.


References
1.
Jaspan J, Towle V, Maselli R, HEROLD K . Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes. Metabolism. 1986; 35(4 Suppl 1):83-92. DOI: 10.1016/0026-0495(86)90193-9. View

2.
Rasekhi H, Karandish M, Jalali M, Mohammadshahi M, Zarei M, Saki A . Phylloquinone supplementation improves glycemic status independent of the effects of adiponectin levels in premonopause women with prediabetes: a double-blind randomized controlled clinical trial. J Diabetes Metab Disord. 2015; 14(1):1. PMC: 4316808. DOI: 10.1186/s40200-014-0127-9. View

3.
El-Kabbani O, Green N, Lin G, Carson M, Narayana S, Moore K . Structures of human and porcine aldehyde reductase: an enzyme implicated in diabetic complications. Acta Crystallogr D Biol Crystallogr. 1994; 50(Pt 6):859-68. DOI: 10.1107/S0907444994005275. View

4.
Raskin P, Rosenstock J . Aldose reductase inhibitors and diabetic complications. Am J Med. 1987; 83(2):298-306. DOI: 10.1016/0002-9343(87)90702-9. View

5.
Iwamoto J, Seki A, Sato Y, Matsumoto H, Takeda T, Yeh J . Vitamin K₂ prevents hyperglycemia and cancellous osteopenia in rats with streptozotocin-induced type 1 diabetes. Calcif Tissue Int. 2010; 88(2):162-8. DOI: 10.1007/s00223-010-9441-5. View